CL2007001787A1 - Muteina recombinante del interferon alfa humano con al menos un sitio de glicosilacion; gen que la codifica; metodo para producir dicho gen y linea celular productora de dicha muteina; composicion farmaceutica que comprende dicha muteina; uso de la m - Google Patents

Muteina recombinante del interferon alfa humano con al menos un sitio de glicosilacion; gen que la codifica; metodo para producir dicho gen y linea celular productora de dicha muteina; composicion farmaceutica que comprende dicha muteina; uso de la m

Info

Publication number
CL2007001787A1
CL2007001787A1 CL200701787A CL2007001787A CL2007001787A1 CL 2007001787 A1 CL2007001787 A1 CL 2007001787A1 CL 200701787 A CL200701787 A CL 200701787A CL 2007001787 A CL2007001787 A CL 2007001787A CL 2007001787 A1 CL2007001787 A1 CL 2007001787A1
Authority
CL
Chile
Prior art keywords
muteine
gen
muteina
humano
codifies
Prior art date
Application number
CL200701787A
Other languages
English (en)
Inventor
Agustin Lopez Ricardo
Original Assignee
Protech Pharma S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protech Pharma S A filed Critical Protech Pharma S A
Publication of CL2007001787A1 publication Critical patent/CL2007001787A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL200701787A 2006-06-20 2007-06-19 Muteina recombinante del interferon alfa humano con al menos un sitio de glicosilacion; gen que la codifica; metodo para producir dicho gen y linea celular productora de dicha muteina; composicion farmaceutica que comprende dicha muteina; uso de la m CL2007001787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP060102627A AR078117A1 (es) 2006-06-20 2006-06-20 Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina

Publications (1)

Publication Number Publication Date
CL2007001787A1 true CL2007001787A1 (es) 2008-02-29

Family

ID=38845168

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200701787A CL2007001787A1 (es) 2006-06-20 2007-06-19 Muteina recombinante del interferon alfa humano con al menos un sitio de glicosilacion; gen que la codifica; metodo para producir dicho gen y linea celular productora de dicha muteina; composicion farmaceutica que comprende dicha muteina; uso de la m

Country Status (7)

Country Link
US (1) US20120134960A1 (es)
EP (1) EP2048158B1 (es)
AR (1) AR078117A1 (es)
CL (1) CL2007001787A1 (es)
CO (1) CO5990175A1 (es)
PE (1) PE20080690A1 (es)
WO (1) WO2008000881A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111944008A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种突变蛋白的方法以及得到的突变体蛋白

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4184917A (en) 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
AU650893B2 (en) 1990-07-10 1994-07-07 Boehringer Ingelheim International Gmbh O-glycosylated alpha-2 interferon
ATE193551T1 (de) 1991-03-18 2000-06-15 Scripps Research Inst Oligosaccharide als enzymsubstrate und - inhibitoren: verfahren und zusammensetzungen
TW263437B (es) 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
IL116730A0 (en) 1995-01-13 1996-05-14 Amgen Inc Chemically modified interferon
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620916B1 (en) 1996-09-26 2003-09-16 Ajinomoto Co., Inc. Modified physiologically active proteins and medicinal compositions containing the same
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
WO2001088117A2 (en) 2000-05-12 2001-11-22 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
CN101724075B (zh) 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
WO2004019856A2 (en) 2002-08-31 2004-03-11 Cj Corp. Glycosylated human interferon alpha isoform
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
ATE337017T1 (de) * 2002-11-15 2006-09-15 Hoffmann La Roche Positionelle isomeren von pegyliertem interferon alpha 2a
US20040180054A1 (en) 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
CN1557479A (zh) 2004-01-16 2004-12-29 深圳市海王英特龙生物技术股份有限公 干扰素脂质体乳膏
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2572751A1 (en) 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
CA2576030A1 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same

Also Published As

Publication number Publication date
PE20080690A1 (es) 2008-08-07
WO2008000881A1 (es) 2008-01-03
WO2008000881A9 (es) 2008-04-24
WO2008000881B1 (es) 2008-02-21
US20120134960A1 (en) 2012-05-31
EP2048158B1 (en) 2013-10-02
AR078117A1 (es) 2011-10-19
CO5990175A1 (es) 2008-12-31
EP2048158A4 (en) 2011-08-10
EP2048158A1 (en) 2009-04-15

Similar Documents

Publication Publication Date Title
CL2007003202A1 (es) Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007003201A1 (es) Composicion farmaceutica liquida que comprende un derivado de ciclodextrina eterificada y un bencimidazol sustituido, donde el derivado de ciclodextrina se selecciona de eter de alfa, beta y gama-ciclodextrina; y uso para el tratamiento de insuficien
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
ATE554785T1 (de) Modifizierte fgf-21 polypeptide und ihre verwendung
CL2013000444A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprende un material de liberacion prolongada, y oxicodona y naloxona, cuya composicion farmaceutica almacenada en condiciones de estres tiene menos de un 4% de sustancias relacionadas con oxicodona y naloxona; y uso de un aglutinante para fabricar dicha composicion.
DE112005003709A5 (de) Mischung zur Herstellung von selbstverdichtendem Beton
IL205734A0 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
CL2007003791A1 (es) Compuestos derivados de piperidina, inhibidores de la proteina quinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para inhibir el crecimiento celular anormal.
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
FI20040365A (fi) Hiilen nanoputket ja niistä valmistetut, säädettävät ominaisuudet omaavat yhdistelmämateriaalit, menetelmä hiilen nanoputkien sekä niiden toiminnallisten yhdistelmämateriaalien valmistamiseksi sekä näistä materiaaleista valmistetut rakenteet ja laitteet
BRPI0717651A2 (pt) Vacinas de peptídeo para cânceres que expressam polipeptídeos mphosph1 ou depdc1
CR9218A (es) Cemento impermeable y composicion sinergica empleada para la obtencion de alta impermeabilidad
EP2048123A4 (en) CEMENT MIXTURE AND CEMENT COMPOSITION USING THE SAME
ATE552170T1 (de) Verfahren und vorrichtung für einen mehrteiligen landeklappezaun
EA201000481A1 (ru) Усовершенствования, относящиеся к трубе
ATE498683T1 (de) Leptin antagonisten
BRPI0717496A2 (pt) Polímeros ramificados e métodos para sua síntese e uso
BRPI0817617A2 (pt) Método para produção de cimento portland de escória e cimento portland de alto-forno
EP2077285A4 (en) FLUORINATED ELASTOMER FOR FORMING A FUEL PIPING COMPONENT AND COMPOSITION THEREWITH
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.
CL2008003799A1 (es) Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
BRPI1014845A2 (pt) "método e instalação para fabricação de clinquer de cimento"